Cancer Treatment Centers of America
(888) 552-6760

Have questions? Call (888) 552-6760 to speak to a cancer information specialist.

The CTCA blog

'Metachronous cancer': A growing concern for cancer survivors


For many survivors, beating cancer brings a welcome sigh of relief. But for some, even those whose cancer never regrows or spreads, it won’t be their last battle with the disease.  Research suggests that a growing percentage of cancer survivors are being diagnosed with “metachronous” cancers—new primary tumors unrelated to the patients’ previous cancers.

Genomic testing's role in the fight against cancer


Just as no two fingerprints are exactly alike, no two tumors are identical. Every cancer is different, even when it affects the same part of the body as another. In recent years, one of the biggest scientific breakthroughs in cancer treatment has involved genomic testing, which allows doctors to understand an individual patient’s cancer at the molecular level, and then figure out options to treat it.

Mastectomies for men on the rise


An uptick in male breast cancer patients opting for preventive mastectomies has some experts concerned, especially given the lack of evidence showing the procedure has long-term benefits.

Reality TV star Daisy Lewellyn's battle with bile duct cancer raises awareness and hope


In a tribute to reality TV star Daisy Lewellyn, who died of bile duct cancer at age 36 on April 8, ESSENCE magazine recalled how the  “Queen of Effortless Chic” brought people together and spread a message of hope and love as she battled her fast-moving cancer.  Few viewers may have heard of bile duct cancer before Lewellyn shared her journey on Bravo’s “Blood, Sweat and Heels” program. But by the end of Season 1, she had taught them much.

Probiotics may help immunotherapy drugs fight cancer


Some patients with melanoma, lung and head and neck cancers are responding strongly to a new class of immunotherapy drugs called checkpoint inhibitors, research shows. But other patients aren’t responding at all. The effort to explain the disparity between cancer patients who benefit from the drugs and those who don’t has led scientists to an unexpected place: the gut—specifically, the microbes taking up residence there.